Fig. 2: PVSRIPO-infected myeloid cells delay tumor growth. | Nature Communications

Fig. 2: PVSRIPO-infected myeloid cells delay tumor growth.

From: Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling

Fig. 2

a Peritoneal exudate cells (PEC) from CD155-tg mice were treated with mock, mRIPO [multiplicity of infection (MOI) of 10], or LPS (100 ng/ml) in vitro; cytokine release was measured and normalized to maximum value for each cytokine across all treatments (n = 2 experiments). b Wt B16 or E0771 cells were mixed with mock or mRIPO-infected CD155-tg PEC and implanted into CD155-tg mice subcutaneous or fat pad, respectively. B16: Mock n = 9, mRIPO n = 8; E0771: n = 9 for both. c E0771 tumor-bearing fat pads were harvested 21 days post E0771 + PEC (−/+mRIPO) implantation and analyzed by flow cytometry (n = 5/group); see Supplementary Fig. 5 for gating strategy. Asterisks indicate t test p < 0.05 (two-tailed; from top to bottom: p = 0.03, 0.01, 0.02, 0.02, 0.01, 0.02), values represent fold-mean mock %positive. d Wt mice bearing B16 tumors were injected with CD155-tg PEC or FLT3L-derived BMDCs after ex vivo pre-treatment with mock or mRIPO (MOI 10; 24 h) as shown; n = 9 mock and mRIPO-infected PEC, n = 8 PEC/BMDC (mock) and mRIPO-infected BMDCs. b, d Mean tumor volume + SEM is shown and p-values are from two-way ANOVA (two-tailed). All experiments were repeated at least twice and a representative series is shown.

Back to article page